<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01214343</url>
  </required_header>
  <id_info>
    <org_study_id>SILIUS Phase III trial</org_study_id>
    <nct_id>NCT01214343</nct_id>
  </id_info>
  <brief_title>Comparing Efficacy of Sorafenib Versus Sorafenib in Combination With Low-dose FP in Patients With Advanced HCC</brief_title>
  <official_title>Randomized Controlled Trial Comparing Efficacy of Sorafenib Versus Sorafenib In Combination With Low Dose Cisplatin /Fluorouracil Hepatic Arterial InfUSion Chemotherapy in Patients With Advanced Hepatocellular Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ministry of Health, Labour and Welfare, Japan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ministry of Health, Labour and Welfare, Japan</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy of sorafenib in combination with low
      dose cisplatin /fluorouracil hepatic arterial infusion chemotherapy in patients with advanced
      hepatocellular carcinoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Sorafenib with Low-dose FP Group

      Sorafenib will be administered orally at a dose of 400 mg (2 x 200 mg tablets) twice daily
      (bid) for 28 days. Cisplatin at the dose of 20mg/m2 will be administered at day 1 and day8,
      and fluorouracil at the dose of 330mg/m2 will be administered continuously at day1-day5, and
      day8-day12 via the implanted catheter system.

      Sorafenib Group

      Sorafenib will be administered orally at a dose of 400 mg (2 x 200 mg tablets) twice daily
      (bid) for 28 days.

      The treatment regimen will be continued until radiographic or symptomatic progression, the
      development of unacceptable toxicity.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>October 2010</start_date>
  <completion_date type="Anticipated">September 2013</completion_date>
  <primary_completion_date type="Anticipated">September 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Overall survival is defined as the time from randomization to death due to any cause</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to progression</measure>
    <time_frame>TTP is defined as the time from randomization to radiological progression.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>PFS is defined as the time from randomization to radiological progression or death due to any cause</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of tumor marker</measure>
    <time_frame>Every 4-6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarker predicting the efficacy</measure>
    <time_frame>Pre and after treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">190</enrollment>
  <condition>Advanced Hepatocellular Carcinoma</condition>
  <condition>Carcinoma</condition>
  <condition>Carcinoma, Hepatocellular</condition>
  <condition>Liver Neoplasms</condition>
  <condition>Neoplasms</condition>
  <arm_group>
    <arm_group_label>Sorafenib with Low-dose FP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Sorafenib</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sorafenib with Low-dose FP</intervention_name>
    <description>Sorafenib will be administered orally at a dose of 400 mg bid for 28 days in a cycle. Cisplatin at the dose of 20 mg/m2 will be administered at day 1 and day8, and fluorouracil at the dose of 330 mg/m2 will be administered continuously at day 1-day 5, and day8-day12 via the implanted catheter system. A cycle is defined as 28 days.</description>
    <arm_group_label>Sorafenib with Low-dose FP</arm_group_label>
    <other_name>Nexavar</other_name>
    <other_name>Low-dose FP</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sorafenib</intervention_name>
    <description>Sorafenib will be administered orally at a dose of 400 mg bid for 28 days in each cycle.A cycle is defined as 28 days.</description>
    <arm_group_label>Sorafenib</arm_group_label>
    <other_name>Nexavar</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. 20 Years and older.

          2. Life expectancy of at least 12 weeks at the pre-treatment evaluation.

          3. Advanced hepatocellular carcinoma with histological evidence on a biopsy specimen, or
             typical findings by dynamic CT or CT during hepatic arteriography/arterioportography.

          4. Not suitable for resection or local ablation therapy or transcatheter arterial
             chemoembolization.

          5. ECOG Performance status of 0 or 1.

          6. Cirrhotic status of Child-Pugh score ≤ 7.

          7. Adequate bone marrow, liver and renal function, as assessed by the following
             laboratory requirements:

               -  Hemoglobin ≥8.5 g/dl

               -  Granulocytes≥1500/μL

               -  Platelet count ≥50,000 /μL

               -  PT-INR ≤ 2.3

               -  Total serum bilirubin ≤ 2 mg/dl

               -  AST(SGOT) and ALT(SGPT) ≤ 6 × upper limit of normal

               -  Serum creatinine ≤ 1.5 × upper limit of normal

               -  Amylase ≤ 2 × upper limit of normal

          8. Written Informed Consent must be obtained.

        Exclusion Criteria:

          1. Previous malignancy (except for cervical carcinoma in situ, adequate treated basal
             cell carcinoma, or superficial bladder tumors [Ta, Tis and T1], early gastric cancer,
             or other malignancies curatively treated &gt; 3 years prior to entry

          2. Renal failure

          3. Any heart disease as follows

               -  Congestive heart failure defined as NYHA class III or IV

               -  Active coronary artery disease or ischemic heart disease such as cardiac
                  infarction within 6 months prior to screening

               -  Serious cardiac arrhythmia

               -  Serious hypertension

          4. Active clinically serious infections except for HBV and HCV

          5. Active chicken pox.

          6. Auditory disorder.

          7. Known history of HIV infection.

          8. Known metastatic or meningeal tumors.

          9. Extrahepatic tumor spread which affects patient's prognosis

         10. History of seizure disorder.

         11. Clinically significant gastrointestinal bleeding within 4 weeks prior to study entry.

         12. Embolization or infarction such as transient ischemic disease, deep vein thrombosis,
             pulmonary embolization.

         13. Any history of treatment as follows:

               -  Treatment with the agent which induces CYP3A4

               -  Surgical procedure within 4 weeks prior to start of study drug

               -  History of organ allograft

         14. Patients unable to swallow oral medications.

         15. Gastrointestinal disease that may affect to the absorption of drug or
             pharmacokinetics.

         16. Medication that may affect to the absorption of drug or pharmacokinetics.

         17. Any disease or disorder that may affect the evaluation of study drug.

         18. Entry to the other clinical trial within 4 weeks prior to entry to this study.

         19. Pregnant or breast-feeding patients.

         20. Known allergy to the investigational agent or any agent given in association with this
             trial.

         21. Substance abuse, medical, psychological or social conditions that, in the judgment of
             the investigator, is likely to interfere with the patient's participation in the study
             or evaluation of the stuy results.

         22. Any condition that is unstable or could jeopardize the safety of the patient and its
             compliance in the study, in the investigator's judgment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Masatoshi Kudo, Professor</last_name>
    <role>Study Chair</role>
    <affiliation>Kinki University Faculty of Medicine, Department of Gastroenterology and Hepatology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Masatoshi Kudo, Professor</last_name>
    <phone>+81-72-366-0221</phone>
    <phone_ext>3149</phone_ext>
    <email>m-kudo@med.kindai.ac.jp</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kazuomi Ueshima, Dr</last_name>
    <phone>+81-72-366-0221</phone>
    <phone_ext>3525</phone_ext>
    <email>kaz-ues@med.kindai.ac.jp</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>National Cancer Center Hospital East</name>
      <address>
        <city>Kashiwa</city>
        <state>Chiba</state>
        <zip>277-8577</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Masafumi Ikeda, Dr.</last_name>
    </contact>
    <investigator>
      <last_name>Masafumi Ikeda, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kurume University Medical Center</name>
      <address>
        <city>Kurume</city>
        <state>Fukuoka</state>
        <zip>839-0863</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Masatoshi Tanaka, Professor</last_name>
    </contact>
    <investigator>
      <last_name>Masatoshi Tanaka, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ogaki Municipal Hospital</name>
      <address>
        <city>Ogaki</city>
        <state>Gifu</state>
        <zip>503-8502</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Takashi Kumada, Dr</last_name>
    </contact>
    <investigator>
      <last_name>Takashi Kumada, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sapporo Medical University</name>
      <address>
        <city>Sapporo</city>
        <state>Hokkaido</state>
        <zip>060-8556</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Junji Kato, Dr.</last_name>
    </contact>
    <investigator>
      <last_name>Junji Kato, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sapporo-Kosei General Hospital</name>
      <address>
        <city>Sapporo</city>
        <state>Hokkaido</state>
        <zip>060-8556</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Takumi Ohmura, Dr.</last_name>
    </contact>
    <investigator>
      <last_name>Takumi Ohmura, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Japanese Red Cross Takamatsu Hospital</name>
      <address>
        <city>Takamatsu</city>
        <state>Kagawa</state>
        <zip>760-0017</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chikara Ogawa, Dr.</last_name>
    </contact>
    <investigator>
      <last_name>Chikara Ogawa, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mie University Hospital</name>
      <address>
        <city>Tsu</city>
        <state>Mie</state>
        <zip>514-8507</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katsuya Shiraki, Dr.</last_name>
    </contact>
    <investigator>
      <last_name>Katsuya Shiraki, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National Hospital Organization Nagasaki Medical Center</name>
      <address>
        <city>Ohmura</city>
        <state>Nagasaki</state>
        <zip>856-8562</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hiromi Ishibashi, Dr.</last_name>
    </contact>
    <investigator>
      <last_name>Hiromi Ishibashi, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kawasaki Medical School Hospital</name>
      <address>
        <city>Kurashiki</city>
        <state>Okayama</state>
        <zip>701-0192</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Keisuke Hino, Dr.</last_name>
    </contact>
    <investigator>
      <last_name>Keisuke Hino, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ikeda Municipal Hospital</name>
      <address>
        <city>Ikeda</city>
        <state>Osaka</state>
        <zip>563-8510</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yasuharu Imai, Dr.</last_name>
    </contact>
    <investigator>
      <last_name>Yasuharu Imai, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kinki University Hospital</name>
      <address>
        <city>Osaka-Sayama</city>
        <state>Osaka</state>
        <zip>589-8511</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Masatoshi Kudo, Professor</last_name>
      <phone>+81-72-366-0221</phone>
      <phone_ext>3149</phone_ext>
      <email>m-kudo@med.kindai.ac.jp</email>
    </contact>
    <contact_backup>
      <last_name>Kazuomi Ueshima, Dr.</last_name>
      <phone>+81-72-366-0221</phone>
      <phone_ext>3525</phone_ext>
      <email>kaz-ues@med.kindai.ac.jp</email>
    </contact_backup>
    <investigator>
      <last_name>Masatoshi Kudo, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kazuomi Ueshima, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kazuto Nishio, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Osaka University Hospital</name>
      <address>
        <city>Suita</city>
        <state>Osaka</state>
        <zip>565-0871</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hiroaki Nagano, Professor</last_name>
    </contact>
    <investigator>
      <last_name>Hiroaki Nagano, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kyorin University Hospital</name>
      <address>
        <city>Mitaka</city>
        <state>Tokyo</state>
        <zip>181-8611</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Junji Furuse, Professor</last_name>
    </contact>
    <investigator>
      <last_name>Junji Furuse, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Musashino Red Cross Hospital</name>
      <address>
        <city>Musashino</city>
        <state>Tokyo</state>
        <zip>180-8610</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Namiki Izumi, Dr.</last_name>
    </contact>
    <investigator>
      <last_name>Namiki Izumi, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Juntendo University Nerima Hospital</name>
      <address>
        <city>Nerima</city>
        <state>Tokyo</state>
        <zip>177-0033</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shigehiro Kokubu, Dr.</last_name>
    </contact>
    <investigator>
      <last_name>Shigehiro Kokubu, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Yamaguchi University Hospital</name>
      <address>
        <city>Ube</city>
        <state>Yamaguchi</state>
        <zip>755-8505</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Isao Sakaida, Prof</last_name>
    </contact>
    <investigator>
      <last_name>Isao Sakaida, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chiba University Hospital</name>
      <address>
        <city>Chiba</city>
        <zip>260-8677</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fumihiko Kanai, Dr.</last_name>
    </contact>
    <investigator>
      <last_name>Fumihiko Kanai, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gifu Municipal Hospital</name>
      <address>
        <city>Gifu</city>
        <zip>500-8513</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eiichi Tomita, Dr.</last_name>
    </contact>
    <investigator>
      <last_name>Eiichi Tomita, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hiroshima City Hospital</name>
      <address>
        <city>Hiroshima</city>
        <zip>730-8518</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yoshiyuki Kobayashi, Dr.</last_name>
    </contact>
    <investigator>
      <last_name>Yoshiyuki Kobayashi, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hiroshima University Hospital</name>
      <address>
        <city>Hiroshima</city>
        <zip>734-8551</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hiroshi Aikata, Dr.</last_name>
    </contact>
    <investigator>
      <last_name>Hiroshi Aikata, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kumamoto University Hospital</name>
      <address>
        <city>Kumamoto</city>
        <zip>860-8556</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yutaka Sasaki, Professor</last_name>
    </contact>
    <investigator>
      <last_name>Yutaka Sasaki, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kyoto University Hospital</name>
      <address>
        <city>Kyoto</city>
        <zip>606-8507</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Etsuro Hatano, Professor</last_name>
    </contact>
    <investigator>
      <last_name>Etsuro Hatano, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Center for Gastroenterological and Hepatological Diseases</name>
      <address>
        <city>Miyazaki</city>
        <zip>880-0003</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hidemori Sakamoto, Dr.</last_name>
    </contact>
    <investigator>
      <last_name>Hidemori Sakamoto, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saiseikai Niigata Dai-ni Hospital</name>
      <address>
        <city>Niigata</city>
        <zip>950-1104</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Toru Ishikawa, Dr.</last_name>
    </contact>
    <investigator>
      <last_name>Toru Ishikawa, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Niigata University Medical and Dental Hospital</name>
      <address>
        <city>Niigata</city>
        <zip>951-8520</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kouhei Akazawa</last_name>
    </contact>
    <investigator>
      <last_name>Kouhei Akazawa</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Okayama University Hospital</name>
      <address>
        <city>Okayama</city>
        <zip>700-8558</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kazuhide Yamamoto, Professor</last_name>
    </contact>
    <investigator>
      <last_name>Kazuhide Yamamoto, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Osaka Red Cross Hospital</name>
      <address>
        <city>Osaka</city>
        <zip>543-8555</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ikuo Osaki, Dr.</last_name>
    </contact>
    <investigator>
      <last_name>Ikuo Osaki, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The University of Tokushima Faculty of Medicine</name>
      <address>
        <city>Tokushima</city>
        <zip>770-8503</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tetsuji Takayama, Dr.</last_name>
    </contact>
    <investigator>
      <last_name>Tetsuji Takayama, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kyoundo Hospital</name>
      <address>
        <city>Tokyo</city>
        <zip>101-0062</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shuntaro Obi, Dr.</last_name>
    </contact>
    <investigator>
      <last_name>Shuntaro Obi, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National Cancer Center Hospital</name>
      <address>
        <city>Tokyo</city>
        <zip>104-0045</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Takushi Okusaka, Dr.</last_name>
    </contact>
    <investigator>
      <last_name>Takushi Okusaka, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>October 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 4, 2010</study_first_submitted>
  <study_first_submitted_qc>October 4, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 5, 2010</study_first_posted>
  <last_update_submitted>June 14, 2011</last_update_submitted>
  <last_update_submitted_qc>June 14, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 15, 2011</last_update_posted>
  <responsible_party>
    <name_title>Kinki University Faculty of Medicine, Department of Gastroenterology and Hepatology</name_title>
    <organization>Kinki University Faculty of Medicine, Department of Gastroenterology and Hepatology</organization>
  </responsible_party>
  <keyword>sorafenib</keyword>
  <keyword>Hepatic intraarterial infusion chemotherapy</keyword>
  <keyword>HAIC</keyword>
  <keyword>Low dose FP</keyword>
  <keyword>cisplatin</keyword>
  <keyword>fluorouracil</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
    <mesh_term>Liver Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sorafenib</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Niacinamide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

